Calliditas Therapeutics AB ADR (CALT): Price and Financial Metrics
GET POWR RATINGS... FREE!
CALT Stock Price Chart Interactive Chart >
CALT Price/Volume Stats
| Current price | $23.56 | 52-week high | $25.49 |
| Prev. close | $23.50 | 52-week low | $10.82 |
| Day low | $23.56 | Volume | 400 |
| Day high | $23.56 | Avg. volume | 14,453 |
| 50-day MA | $20.06 | Dividend yield | N/A |
| 200-day MA | $17.81 | Market Cap | 701.76M |
Calliditas Therapeutics AB ADR (CALT) Company Bio
Calliditas Therapeutics AB provides pharmaceutical products for patients with niche indications. It focuses on development and commercialization of the product candidate Nefecon intended for treatment of patients with the inflammatory renal disease IgA nephropathy. The company was founded by Mikael Bender and Bengt Åke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.
Latest CALT News From Around the Web
Below are the latest news stories about CALLIDITAS THERAPEUTICS AB that investors may wish to consider to help them evaluate CALT as an investment opportunity.
3 Supercharged Stocks Near 52-Week Highs That Could Keep ClimbingThe main stock indexes are way down over the past year, but quite a few under-the-radar stocks have bucked the trend. Reata Pharmaceuticals (NASDAQ: RETA) was a clinical-stage biopharmaceutical company until the U.S. Food and Drug Administration (FDA) approved its first treatment on Feb. 28, 2023. Reata's first approved product, Skyclarys, is the first and only drug approved to treat Friedreich's ataxia, an ultra-rare neuromuscular disease. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday! |
Calliditas Plans To File For Complete FDA Approval For Rare Kidney Disease Drug After Positive Phase 3 DataCalliditas Therapeutics AB (NASDAQ: CALT) announced topline results from the Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon (TARPEYO/Kinpeygo (budesonide) delayed-release capsules) versus placebo in patients with primary IgA nephropathy (IgAN). The trial studied Nefecon on primary IgA nephropathy (IgAN) patients who were also on RAS inhibitor therapy. The drug demonstrated a "highly statistically significant benefit" over the placebo in two years, with nine months of t |
Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA NephropathyCalliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced positive topline results from the global, randomized, double-blind, placebo-controlled Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon (TARPEYO®/Kinpeygo® (budesonide) delayed release capsules) versus placebo in patients with primary IgA nephropathy (IgAN). |
Analyst Sits On Fence While Initiating Calliditas Citing 'Near-Term Opportunity But Longer-Term Questions'Guggenheim initiated coverage on Calliditas Therapeutics AB (NASDAQ: CALT) with a Neutral rating and an $18 price target. The analyst is impressed with the data Tarpeyo has generated in Immunoglobulin A Nephropathy (IgAN) to date and the initial success the company has had with the commercial rollout of the product. While the analyst commends the Calliditas team for their progress with Tarpeyo in IgAN, including obtaining FDA Accelerated Approval and EU Conditional Approval, it notes mixed physi |
CALT Price Returns
| 1-mo | 27.28% |
| 3-mo | 38.59% |
| 6-mo | 55.35% |
| 1-year | 18.57% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 38.59% |
| 2022 | -31.34% |
| 2021 | -26.35% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...